Upgrade to SI Premium - Free Trial

RBC Capital Reiterates Sector Perform Rating on Pacira Pharmaceuticals (PCRX)

May 1, 2026 4:18 AM
RBC Capital analyst Gregory Renza reiterated a Sector Perform rating and $24.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments